Articles related to ALZHEIMER'S/DEMENTIA

A recent study found a 69 percent increased risk of Alzheimer’s diagnosis within a year of COVID-19 infection in individuals aged 65 years and older. This significant link between viral infections and Alzheimer’s disease could have major implications for our understanding of neurodegenerative diseases and their treatment.

Leqembi, a newly FDA-approved drug, has shown promising results in clinical trials, resulting in a 28% slower decline in Alzheimer’s patients compared to placebo. This equates to an additional four to five months of retained function.

The recent study from CTAD 2023 has demonstrated the potential of p-tau217 as a promising biomarker for preclinical Alzheimer’s disease. This finding could significantly enhance our ability to detect Alzheimer’s at its earliest stages and initiate timely interventions.

Recent findings suggest that Candida albicans, a common fungus, can enter the brain and generate toxic protein fragments similar to those seen in Alzheimer’s disease. This discovery could potentially open new avenues for understanding and treating Alzheimer’s.

The discovery that irisin, an exercise-induced hormone, significantly reduces amyloid-β deposits opens up new therapeutic strategies for Alzheimer’s disease. This breakthrough underscores the importance of exercise and its far-reaching implications on cognitive health.

Discover how Labcorp’s new ATN Profile can revolutionize your approach to diagnosing Alzheimer’s disease.